Business Context and Reporting Period
Company: Aytu BioScience, Inc. (trading as AYTU on NASDAQ)
Filing Type: Form 8-K (Current Report)
Date of Report: October 11, 2019
Event: Entry into a Material Definitive Agreement for a private placement offering.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $10.0 million from the sale of Series F Convertible Preferred Stock and Warrants.
- Estimated Net Proceeds: Approximately $9.2 million.
- Use of Proceeds: General corporate purposes, including working capital.
- Placement Agent Fees: 8% of gross proceeds plus expense reimbursement capped at $65,000.
- Preferred Stock Conversion Price: $1.00 per share (subject to adjustment).
- Warrant Exercise Price: $1.25 per share.
- Warrant Expiration: Five years from the effectiveness of the registration statement covering the shares.
Material Changes and Transaction Structure
The Company entered into Securities Purchase Agreements with two institutional accredited investors. The transaction involves:
- Series F Convertible Preferred Stock: Non-convertible until shareholder approval is obtained. Subject to anti-dilution provisions until the earlier of two years from issuance or 85% conversion.
- Ownership Limitations: Holders cannot convert if it results in beneficial ownership exceeding 4.99% (with an election available for up to 9.99% or 40% for specific investors).
- Warrants: Exercisable only after shareholder approval and subject to registration or exemption rules.
- Closing Date: Expected on or about October 16, 2019.
Guidance, Risks, and Contingencies
- Regulatory Contingency: Conversion of Preferred Stock and exercise of Warrants are contingent upon obtaining shareholder approval as required by Nasdaq rules.
- Registration Rights: The Company agreed to file registration statements for the resale of Conversion Shares and Warrant Shares.
- Unregistered Sale: Securities are sold under Section 4(a)(2) and Regulation D exemptions; resale is restricted until registration or exemption applies.
- Financial Impact: The filing does not provide specific revenue, profit, or cash flow metrics for the reporting period, as it focuses solely on the capital raise event.
Investor Verification Checklist
- Verify the status of the shareholder approval required for conversion and warrant exercise.
- Confirm the actual closing date and final net proceeds received.
- Review the filed Registration Rights Agreement for specific timelines on filing the registration statement.
- Monitor the Company's cash position to assess the impact of the $9.2 million net proceeds on working capital.
- Check for any subsequent filings regarding the effectiveness of the registration statement for the underlying shares.